Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
By Ross Levine, MD
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in M
...view more
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
Author Information
By Ross Levine, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center
By Ross Levine, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center
https://www.asia.elsevierhealth.com/non-cml-myeloproliferative-diseases-an-issue-of-hematologyoncology-clinics-of-north-america-9781455749416.html300204Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North Americahttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9781455749416_7.jpg89.0998.99USDInStock/Clinics/Medicine & Surgery/Oncology/Medicine/Oncology/Clinics/Clinics/Medicine/Oncology/Japan Titles43887254335180505458550546665255041525986752631601418269243350884886536505455351451205259833Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis. Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.00add-to-cart97814557494162012ProfessionalBy Ross Levine, MD20121Book152w x 229h (6.00" x 9.00")Saunders240Oct 8, 2012IN STOCKBy <STRONG>Ross Levine</STRONG>, MD, Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer CenterClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
